Neuro-Oncology Advances : Impact Factor & More
eISSN: 2632-2498
Open AccessShare this on:
Key Metrics
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Neuro-Oncology Advances
Neuro-Oncology Advances Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | Oxford University Press |
| Language | English |
| Article Processing Charges | GBP 1500 | USD 2206 |
| Publication Time | 12 |
| Editorial Review Process | Peer review |
| General Details | |
| Publication Details | |
| Publication Time | 12 |
| Waiver Policy | Visit website |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Neuro-Oncology Advances ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Neuro-Oncology Advances
MEK inhibitors for neurofibromatosis type 1-associated central and peripheral nervous system tumors.
- 28 Apr 2026
- Neuro-oncology advances
From blunt tools to bullseyes: The impact of targeted therapy in pediatric neuro-oncology.
- 28 Apr 2026
- Neuro-oncology advances
Spinal high-grade astrocytoma with piloid features arising in a patient with molecularly confirmed cerebellar pilocytic astrocytoma.
- 20 Apr 2026
- Neuro-oncology advances
Cancer-related fatigue among adult patients living with cancer in Ethiopia: A systematic review and meta-analysis
- 17 Apr 2026
- Neuro-Oncology Advances
MGMTai: O6-methylguanine-DNA methyltransferase (MGMT) methylation prediction in isocitrate dehydrogenase (IDH)-wild type glioblastoma to direct temozolomide therapy
- 16 Apr 2026
- Neuro-Oncology Advances
Beyond cell cycle control: CDKN2A loss is associated with altered NAD+ metabolic states and increased sensitivity to NAMPT inhibition in glioblastoma
- 13 Apr 2026
- Neuro-Oncology Advances
MEK inhibitors for neurofibromatosis type 1-associated central and peripheral nervous system tumors.
- 28 Apr 2026
- Neuro-oncology advances
From blunt tools to bullseyes: The impact of targeted therapy in pediatric neuro-oncology.
- 28 Apr 2026
- Neuro-oncology advances
Spinal high-grade astrocytoma with piloid features arising in a patient with molecularly confirmed cerebellar pilocytic astrocytoma.
- 20 Apr 2026
- Neuro-oncology advances
Cancer-related fatigue among adult patients living with cancer in Ethiopia: A systematic review and meta-analysis
- 17 Apr 2026
- Neuro-Oncology Advances
MGMTai: O6-methylguanine-DNA methyltransferase (MGMT) methylation prediction in isocitrate dehydrogenase (IDH)-wild type glioblastoma to direct temozolomide therapy
- 16 Apr 2026
- Neuro-Oncology Advances
Beyond cell cycle control: CDKN2A loss is associated with altered NAD+ metabolic states and increased sensitivity to NAMPT inhibition in glioblastoma
- 13 Apr 2026
- Neuro-Oncology Advances
FAQs on Neuro-Oncology Advances
How many articles did Neuro-Oncology Advances publish last year? 
Who is the publisher of Neuro-Oncology Advances?
